T
TCR2 Therapeutics Inc
F:2K7
TCR2 Therapeutics Inc
F:2K7
Price:
1.442
EUR
3.07%
Market Closed
Market Cap:
€56.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
T
|
TCR2 Therapeutics Inc
F:2K7
|
US |
|
CSX Corp
NASDAQ:CSX
|
US |
|
QuakeSafe Technologies Co Ltd
SZSE:300767
|
CN |
|
Enel Chile SA
NYSE:ENIC
|
CL |
|
Getty Realty Corp
F:GRL
|
US |
|
P
|
Prime Number Acquisition I Corp
NASDAQ:NCNC
|
SG |
|
F
|
Fujian Boss Software Corp
SZSE:300525
|
CN |
|
Park Ha Biological Technology Co Ltd
NASDAQ:PHH
|
CN |
|
Aperam SA
OTC:APEMY
|
LU |
|
S
|
Southern Cable Group Bhd
KLSE:SCGBHD
|
MY |
|
R1 RCM Inc
NASDAQ:RCM
|
US |
|
T
|
Toyo Corp
XMUN:TOY
|
JP |
|
India Power Corporation Ltd
NSE:DPSCLTD
|
IN |
|
Bank of Chengdu Co Ltd
SSE:601838
|
CN |
|
Amphenol Corp
NYSE:APH
|
US |
|
S
|
Shanghai Urban Architecture Design Co Ltd
SZSE:300983
|
CN |
|
Ahluwalia Contracts (India) Ltd
NSE:AHLUCONT
|
IN |
|
Vardhman Polytex Ltd
NSE:VARDMNPOLY
|
IN |
|
Recticel NV
XBRU:RECT
|
BE |
|
M
|
Manutan International SA
LSE:0F6I
|
FR |
|
Sanoma Oyj
F:SNQB
|
FI |
Balance Sheet
Balance Sheet Decomposition
TCR2 Therapeutics Inc
TCR2 Therapeutics Inc
Balance Sheet Decomposition is not available for
TCR2 Therapeutics Inc
TCR2 Therapeutics Inc
Balance Sheet
TCR2 Therapeutics Inc
TCR2 Therapeutics Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
8
|
20
|
48
|
65
|
94
|
223
|
33
|
|
| Cash Equivalents |
8
|
20
|
48
|
65
|
94
|
223
|
33
|
|
| Short-Term Investments |
8
|
0
|
76
|
93
|
134
|
43
|
116
|
|
| Other Current Assets |
1
|
1
|
2
|
5
|
8
|
11
|
28
|
|
| Total Current Assets |
17
|
21
|
126
|
163
|
236
|
276
|
178
|
|
| PP&E Net |
1
|
1
|
2
|
5
|
10
|
45
|
29
|
|
| PP&E Gross |
1
|
1
|
2
|
5
|
10
|
45
|
29
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
2
|
3
|
5
|
6
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
0
|
1
|
2
|
2
|
|
| Total Assets |
18
N/A
|
22
+20%
|
129
+488%
|
169
+30%
|
246
+46%
|
323
+31%
|
208
-36%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
0
|
3
|
3
|
2
|
2
|
3
|
|
| Accrued Liabilities |
0
|
1
|
3
|
5
|
6
|
16
|
61
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Liabilities |
1
|
1
|
6
|
8
|
9
|
19
|
64
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
1
|
23
|
3
|
|
| Total Liabilities |
1
N/A
|
1
+30%
|
6
+354%
|
8
+37%
|
10
+19%
|
42
+336%
|
67
+61%
|
|
| Equity | ||||||||
| Common Stock |
29
|
47
|
209
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
12
|
26
|
86
|
183
|
250
|
350
|
501
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
343
|
486
|
631
|
643
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
17
N/A
|
21
+20%
|
124
+494%
|
160
+30%
|
237
+47%
|
281
+19%
|
141
-50%
|
|
| Total Liabilities & Equity |
18
N/A
|
22
+20%
|
129
+488%
|
169
+30%
|
246
+46%
|
323
+31%
|
208
-36%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
23
|
23
|
24
|
24
|
34
|
38
|
39
|
|
Switch to:
Switch to:
See Also
Discover More
